Compare VRTX & PANW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRTX | PANW |
|---|---|---|
| Founded | 1989 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Computer peripheral equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7B | 126.9B |
| IPO Year | 1991 | 2012 |
| Metric | VRTX | PANW |
|---|---|---|
| Price | $464.65 | $181.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 38 |
| Target Price | ★ $501.42 | $229.20 |
| AVG Volume (30 Days) | 1.4M | ★ 5.8M |
| Earning Date | 02-12-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.22 | 1.58 |
| Revenue | ★ $11,723,300,000.00 | $9,556,500,000.00 |
| Revenue This Year | $10.93 | $16.49 |
| Revenue Next Year | $8.44 | $13.21 |
| P/E Ratio | ★ $31.08 | $116.49 |
| Revenue Growth | 10.33 | ★ 15.30 |
| 52 Week Low | $362.50 | $144.15 |
| 52 Week High | $519.68 | $223.61 |
| Indicator | VRTX | PANW |
|---|---|---|
| Relative Strength Index (RSI) | 55.63 | 38.87 |
| Support Level | $429.00 | $187.29 |
| Resistance Level | $487.52 | $194.07 |
| Average True Range (ATR) | 12.79 | 5.28 |
| MACD | -2.15 | -0.08 |
| Stochastic Oscillator | 57.70 | 21.94 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.